Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2023-10-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物关于变更会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's accounting firm. It details the new and former accounting firms, reasons for the change, communication with the firms, and the approval process including board and independent directors' opinions. It does not contain any financial statements or audit reports themselves, but rather informs about the change of auditor and related procedural details. The document length is 3535 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this is not an Audit Report (AR) but an announcement about auditor change, which fits best under Regulatory Filings (RNS) as it is a regulatory disclosure that does not fit other specific categories.
2023-10-30 Chinese
安旭生物第二届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the Supervisory Board meeting of Hangzhou Anxu Biotechnology Co., Ltd. It includes approval of the 2023 Q3 report, continued use of raised funds for cash management, and change of auditor. The document references the 2023 Q3 report and other announcements but does not contain the actual financial data or the full report itself. The document length is short (1468 characters) and it states that detailed content is disclosed on the Shanghai Stock Exchange website. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement of meeting resolutions and related disclosures, not the full quarterly report or audit report itself.
2023-10-30 Chinese
安旭生物关于继续使用超募资金及部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Hangzhou Anxu Biotech Co., Ltd. regarding the continued use of excess raised funds and some idle raised funds for cash management. It details the board resolutions, investment purposes, risk controls, and approvals related to the use of raised funds for short-term, low-risk financial products. The document includes references to regulatory approvals, board and supervisory committee meetings, and independent director opinions. It does not contain financial statements or detailed financial performance data but rather focuses on the company's financing and capital management activities. The document length is 4637 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it provides an update on the company's use of capital raised through financing activities for cash management purposes.
2023-10-30 Chinese
安旭生物关于召开2023年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice for convening the 2023 second extraordinary general meeting of shareholders of Hangzhou Anxu Biotechnology Co., Ltd. It includes details about the meeting date, voting methods, agenda items (such as the proposal to change the accounting firm), registration procedures, and proxy authorization forms. There is no financial data, earnings information, or detailed report content. The document is an announcement about the meeting and its logistics rather than the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2023-10-30 Chinese
安旭生物关于部分信托产品逾期兑付的风险提示公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement regarding overdue payments on certain trust products invested by the company. It details the investment amount, risk factors, communication with the trustee, and potential impacts on the company's financials. The document is relatively short (2020 characters) and serves as a disclosure of a specific financial risk event rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. It is not an earnings release, annual report, or interim report. It is also not a certification or officer attestation. The content fits best under a regulatory announcement category that informs investors about a material risk event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-10-08 Chinese
民生证券股份有限公司关于安旭生物2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023年半年度持续督导跟踪报告' which translates to '2023 Semi-Annual Continuous Supervision Follow-up Report'. It is issued by a sponsoring institution (民生证券股份有限公司) responsible for ongoing supervision of a listed company (杭州安旭生物科技股份有限公司). The content includes detailed descriptions of supervision activities, risk factors, financial data for the first half of 2023, core competitiveness, R&D progress, and compliance with fundraising usage. The document contains substantive financial data and analysis for a half-year period (2023 January to June), including income, profit, cash flow, and asset changes. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year with actual financial statements and analysis. The document is not a brief announcement or a certification letter, but a detailed report. Therefore, the correct classification is IR with high confidence. H1 2023
2023-09-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.